Would you still offer adjuvant osimertinib to patients who elect not to receive chemotherapy in resected EGFR mutated lung cancer?

Yes- while it is important to keep in mind that platinum-based adjuvant chemotherapy confers OS benefit in the appropriate setting, adjuvant chemotherapy prior to osimertinib/placebo randomization was not mandatory in the ADAURA study design. In the updated analysis presented at ESMO 2022 by Tsuboi ...